Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
3 Magnificent Growth Stocks to Buy in March
It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Healthcare Dive26d
A new, non-opioid pain drug is here. Getting it to patients could be agony.
Expectations around Journavx are high. With the U.S. still mired in an overdose crisis that’s killed hundreds of thousands of people, Vertex is positioning its medicine as a valuable alternative ...
FiercePharma26d
Vertex lays out plan to increase access and launch non-opioid pain reliever Journavx
During a quarterly earnings presentation (PDF) on Monday, Vertex executives said the company expects to begin shipping Journavx by the end of this month. In the early phase of the launch ...
2 Minute Medicine5d
Vertex: non-opioid pain reliever Journavx shows success in post operative pain control
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...
MoneyWeek on MSN2d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Vertex Pharmaceuticals Leads 3 Value Stocks Offering Estimated Intrinsic Value
As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly seeking opportunities in undervalued stocks that may offer intrinsic value ...